Seelos therapeutics announces top line results from sls-002 phase ii study in adults with major depressive disorder at imminent risk of suicide

Sls-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality robust response and remission rates were observed using the montgomery-Åsberg depression rating scale (madrs) results demonstrate the therapeutic potential of sls-002 to address imminent suicidality sls-002 was well-tolerated, with no evidence of new or unique adverse events and there were no deaths reported in the study the company will host a webcast with dr. david v sheehan, today, wednesday, september 20th at 8:00 a.m. et new york , sept.
SEEL Ratings Summary
SEEL Quant Ranking